A study published in The Lancet confirms the one-shot Sputnik Light vaccine has a high safety profile and induces a strong humoral and cellular immune response both in the seronegative and seropositive groups

The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces a new publication by the Gamaleya Center in The Lancet, one of the world's most respected medical journals, showing the one-shot Sputnik Light vaccine against coronavirus demonstrates a high safety profile and induces a strong humoral and cellular immune response. RDIF has sponsored the study.

The study on the safety, tolerability and immunogenicity of the Sputnik Light vaccine has confirmed that the vaccine induces strong humoral and cellular immune response both in the seronegative and seropositive groups.

Most of the solicited adverse reactions observed during the study were mild or moderate. No serious adverse events were detected.

One-shot Sputnik Light is a highly effective vaccine when used both on a standalone basis and applied as a booster. Sputnik Light has been authorized in more than 15 countries with the registration process ongoing in a further 30 countries.

The earlier findings by the Gamaleya Centre based on data from 28,000 subjects in Moscow have demonstrated the Sputnik Light vaccine administered standalone has 70% efficacy against infection from the Delta variant of coronavirus during the first three months after vaccination. The vaccine is 75% effective among subjects under the age of 60.

Efficacy of one-shot Sputnik Light as a booster against Delta variant for other vaccines will be close to the efficacy against the Delta variant of the Sputnik V vaccine: over 83% against infection and over 94% against hospitalization.

Sputnik Light has demonstrated superior efficacy compared with some two-shot vaccines, which have shown a major decline in efficacy against the Delta variant to less than 50% five months after injection. Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations.

Sputnik Light is a safe and highly effective vaccine against Covid as confirmed by the real-world vaccination data. In particular, the vaccine has demonstrated the efficacy of between 78.6-83.7% among the elderly as confirmed by the Ministry of Health of Buenos Aires,